← back to search

Michal Vrablı́k

Charles University · CZ
Area of research
Surgery · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Cancer, Lipids, and Metabolism, and Lipid metabolism and disorders.
h-index
40
citations
8,143
works
347
NIH funding
primary concept
Medicine
email

Recent publications

Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
New England Journal of Medicine 2025cited by 30position: middledoi
Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
Progress in Cardiovascular Diseases 2023cited by 70position: middledoi
The time is now: Achieving FH paediatric screening across Europe – The Prague Declaration
PubMed 2022cited by 28position: middledoi
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
Atherosclerosis 2021cited by 136position: middledoi
Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP)
Progress in Cardiovascular Diseases 2021cited by 62position: middledoi
EU-Wi<i>d</i>e Cross-Section<i>a</i>l Obser<i>v</i>at<i>i</i>o<i>n</i>al Study of Lipid-Modifying Therapy Use in Se<i>c</i>ondary and Pr<i>i</i>mary Care: the DA VINCI study
European Journal of Preventive Cardiology 2020cited by 743position: middledoi
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential
Cardiovascular Diabetology 2019cited by 142position: middledoi
Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials
Pharmacological Research 2019cited by 128position: middledoi
The Role of Nutraceuticals in Statin Intolerant Patients
Journal of the American College of Cardiology 2018cited by 270position: middledoi
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
New England Journal of Medicine 2017cited by 628position: middledoi
Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
Archives of Medical Science 2017cited by 286position: middledoi
Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
Nutrition Reviews 2017cited by 285position: middledoi
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
European Heart Journal Supplements 2016cited by 101position: middledoi
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapy
Atherosclerosis Supplements 2015cited by 84position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Željko Reiner · University Hospital Centre Zagreb5 papers (2015–2023)Michel Farnier · University of Cape Town4 papers (2015–2023)Alberico L. Catapano · Novo Nordisk (United Kingdom)3 papers (2015–2021)Lâle Tokgözoğlu · Hacettepe University3 papers (2015–2021)Maciej Banach · University of Southampton3 papers (2019–2023)Alberto Zambon · MultiMedica3 papers (2015–2021) · 3 papers (2015–2021)Pasquale Perrone Filardi · University of Naples Federico II2 papers (2015–2016)Roberto Ferrari · German Centre for Cardiovascular Research2 papers (2015–2016) · 2 papers (2015–2016) · 2 papers (2015–2016) · 2 papers (2015–2016)Meral Kayıkçıoğlu · Ege University2 papers (2015–2016) · 2 papers (2015–2016)Margus Viigimaa · European Atherosclerosis Society2 papers (2015–2016)Jean Ferrières · Clinique Pasteur2 papers (2015–2016)Carlos Aguíar · Universidade Federal de Juiz de Fora2 papers (2015–2016)Éric Bruckert · Sorbonne Université2 papers (2019–2021)Moses Elisaf · Aristotle University of Thessaloniki2 papers (2015–2016)Francesco Cosentino · Linköping University2 papers (2015–2016)